Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Exley

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Immunity|January 21, 2016
What Makes MAITs Wait?Mark A Exley
Hepatology (Baltimore, Md.)|October 16, 2004
To be or not to be NKT: natural killer T cells in the liverMark A Exley, Margaret James Koziel
Clinical Immunology (Orlando, Fla.)|May 26, 2019
iNKT cells and hematopoietic stem cell transplantation: Two-phase activation of iNKT cells may improve outcomeMohammad Fereidouni, Afshin Derakhshani, Mark A Exley
Molecular Immunology|February 14, 2021
Exploiting CD1-restricted T cells for clinical benefitMark A Exley, Paolo Dellabona, Giulia Casorati
Frontiers in Immunology|September 26, 2025
Innate iNKT cells: from biological insight to clinical impactAntonia Rotolo, Nicola J Mason, Mark A Exley
Current Protocols in Immunology|September 4, 2010
Isolation and functional use of human NKT cellsMark A Exley, Brian Wilson, Steven P Balk
Immunology|June 24, 2006
The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent mannerGillian A Lang, Mark A Exley, Mark L Lang
The Journal of Endocrinology|September 18, 2014
Interplay between the immune system and adipose tissue in obesityMark A Exley, Laura Hand, Donal O'Shea, et al.
Current Protocols in Immunology|November 2, 2017
Isolation and Functional Use of Human NKT CellsMark A Exley, S Brian Wilson, Steven P Balk
Frontiers in Immunology|March 22, 2018
Novel Approaches to Exploiting Invariant NKT Cells in Cancer ImmunotherapyBenjamin J Wolf, Jiyoung Elizabeth Choi, Mark A Exley
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Immunity|January 21, 2016
What Makes MAITs Wait?Mark A Exley
Hepatology (Baltimore, Md.)|October 16, 2004
To be or not to be NKT: natural killer T cells in the liverMark A Exley, Margaret James Koziel
Clinical Immunology (Orlando, Fla.)|May 26, 2019
iNKT cells and hematopoietic stem cell transplantation: Two-phase activation of iNKT cells may improve outcomeMohammad Fereidouni, Afshin Derakhshani, Mark A Exley
Molecular Immunology|February 14, 2021
Exploiting CD1-restricted T cells for clinical benefitMark A Exley, Paolo Dellabona, Giulia Casorati
Frontiers in Immunology|September 26, 2025
Innate iNKT cells: from biological insight to clinical impactAntonia Rotolo, Nicola J Mason, Mark A Exley
Current Protocols in Immunology|September 4, 2010
Isolation and functional use of human NKT cellsMark A Exley, Brian Wilson, Steven P Balk
Immunology|June 24, 2006
The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent mannerGillian A Lang, Mark A Exley, Mark L Lang
The Journal of Endocrinology|September 18, 2014
Interplay between the immune system and adipose tissue in obesityMark A Exley, Laura Hand, Donal O'Shea, et al.
Current Protocols in Immunology|November 2, 2017
Isolation and Functional Use of Human NKT CellsMark A Exley, S Brian Wilson, Steven P Balk
Frontiers in Immunology|March 22, 2018
Novel Approaches to Exploiting Invariant NKT Cells in Cancer ImmunotherapyBenjamin J Wolf, Jiyoung Elizabeth Choi, Mark A Exley
Pageof 8